Inclusion Criteria:

Non-Hodgkin's lymphoma patients with prior therapy who satisfy the conditions listed
below. No restrictions regarding gender.

- Patients with histologically or cytologically confirmed indolent B cell Non-Hodgkin's
lymphoma or mantle cell lymphoma.

- Patients who had not received treatment for at least 4 weeks (for at least 12 weeks
in the case of antibody therapy) after completion of prior therapy and who are judged
to carry no effect from the prior therapy.

- Patients aged from 20 to less than 75 years.

- Performance Status (P.S.): 0 or 1.

- Patients with adequately maintained organ functions (e.g., bone marrow, heart, lung,
liver, and kidney functions).

- Patients from whom written consent to participate in this study has been obtained.

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded.

- Patients with apparent infections.

- Patients with serious complications (hepatic failure or renal failure).

- Patients with complication or history of serious heart failure (e.g. cardiac
infarction, ischemic heart disease).

- Patients with serious digestive symptoms (nausea/ vomiting/ diarrhea).

- Patients who are known to be positive for HBV, HCV or HIC.

- Patients receiving other investigational drugs within 3 months before registration in
the study.

- Patients with allogenic bone-marrow transplant.

- Women who are pregnant, of childbearing potential, or lactating.

- Patients who do not agree to contraception.

- Otherwise, patients who are judged by the investigator as being unsuitable for
inclusion in the study.